This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BBB Therapeutics B.V.
Drug Names(s): Glutathione PEGylated Liposomal Doxorubicin
Description: 2B3-101, a glutathione PEGylated liposomal doxorubicin, utilizes the Company's proprietary G-Technology delivery platform and is prepared by the pre-insertion of GSH-PEG micelles into lipids before extrusion and active loading of doxorubicin.
Deal Structure: In September 2014, to-BBB announced significant additions to complete its new management team as well as changing its name from to-BBB technologies B.V. to BBB Therapeutics B.V.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: